Welcome to our dedicated page for CLXT news (Ticker: CLXT), a resource for investors and traders seeking the latest updates and insights on CLXT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLXT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLXT's position in the market.
Calyxt, Inc. (NASDAQ: CLXT) announced an exclusive licensing agreement with S&W Seed Company for an improved quality alfalfa seed in the U.S. This marks Calyxt's first commercial trait license agreement, with potential revenues exceeding $10 million based on U.S. sales projections. The new alfalfa, branded as IQ Alfalfa, aims to enhance livestock performance through improved digestibility and quality. Field trials are planned for 2021, and S&W Seed Company will support research on yield and animal performance.
Calyxt, Inc. (NASDAQ: CLXT) will host a Virtual Analyst Day on November 17, 2020, at 4:00 p.m. Eastern time. This event will feature an overview of the company’s research and development pipeline and a business update from management, followed by a Q&A session with analysts. The event can be accessed via a webcast link provided in the announcement. A replay will be available post-event until December 1, 2020. For further inquiries, contact the investor relations team.
Calyxt, a plant-based technology company, has completed a registered direct offering of 3,750,000 shares of common stock, priced at $4.00 per share, totaling gross proceeds of $15 million. Cellectis S.A., the majority shareholder, purchased 1,250,000 shares. The funds will be used for general corporate purposes, advancing product development and TALEN® technology. The offering was conducted under an effective registration statement with the SEC, utilizing a prospectus filed on October 16, 2020.
Calyxt, Inc. (NASDAQ: CLXT) announced a registered direct offering of 3,750,000 shares at $4.00 per share, expected to close on October 20, 2020. Majority shareholder Cellectis S.A. will purchase 1,250,000 shares. The gross proceeds are projected at $15 million, aimed at advancing product development and enhancing TALEN® technology. H.C. Wainwright & Co. serves as the exclusive placement agent. This offering is facilitated under an effective shelf registration statement with the SEC, and a final prospectus will be available on the SEC website.
Calyxt, Inc. (NASDAQ: CLXT) has appointed Sarah Reiter as Vice President of Business Development. With over 25 years of experience in agribusiness, Ms. Reiter aims to enhance Calyxt's go-to-market strategies by leveraging her expertise in international business development and partnerships. Previously, she served as Chief Commercial Officer at Arcadia Biosciences, leading global commercialization efforts. This strategic hire is expected to strengthen Calyxt's market position in plant-based innovations amidst growing consumer demand.
Calyxt, Inc. (NASDAQ: CLXT) will hold a conference call on November 5, 2020, at 4:30 p.m. EST to discuss its Q3 2020 results, with a press release to be issued beforehand. CEO Jim Blome and CFO Bill Koschak will lead the call, which will include a Q&A session. Interested parties can access the conference via 1-877-407-0789 for US callers or 1-201-689-8562 for international callers. The call will be live-streamed and available for replay. For further information, visit Calyxt's investor relations website.